Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27203569 | 0.88 | MEN1 (0.48) | GPR119MEN1MAPTTSHRKMT2A | |
| SCHEMBL14802410 | 0.85 | SMN1; SMN2 (0.60) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL29913781 | 0.85 | SMN1; SMN2 (0.60) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL24480734 | 0.84 | GPR119 (0.63) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL30602883 | 0.84 | GPR119 (0.63) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL31048027 | 0.83 | GPR119 (0.51) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL25738114 | 0.83 | GPR119 (0.48) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL27203610 | 0.83 | GPR119 (0.53) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL27203482 | 0.83 | GPR119 (0.46) | GPR119HRH3MEN1MAPTTSHR | |
| SCHEMBL653985 | 0.82 | CHRNB4 (0.48) | GPR119MEN1MAPTTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132522-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132522-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | GPR119 2236/4885HRH3 2784/4885MEN1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.